DUBLIN, Aug. 17, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/l5lx3z/investigation) has announced the addition of the "Investigation Report on China's Glipizide Market, 2010-2019" report to their offering.

As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, glipizide and glimepiride are the common drugs in the class of sulfonylurea.

As the first-line drug for type 2 diabetes, glipizide belongs to the second generation of sulfonylurea and it works by stimulating insulin secretion. Developed by Pfizer, glipizide was approved by the FDA to enter the market in April 1994. Glipizide in the Chinese market mainly comes from Pfizer (Trade Name: Glucotrol Common Name: Glipizide Controlled Release Tablets), Disha Pharmaceutical Group (Trade Name: Dishapian Common Name: Glipizide Tablets) and Yangtze River Pharmaceutical Group (Trade Name: Qinsu Common Name: Glipizide Extended Release Tablets). Although quite a lot local enterprises produce gliclazide, they all took up a small market share.

According to this market survey, in 2014, Pfizer (US) took up a market share of about 86% for sales value in China while other companies like Shandong Wanjie High-tech Co., Ltd, Yangtze River Pharmaceutical Group and Disha Pharmaceutical Group shared the rest of the market share. The annual sales value of glipizide stayed at CNY 50-60 million during the period of 2005-2014.

Key Topics Covered:

1 Related Concepts of Glipizide

2 Market Profile of Glipizide in China

3 Survey on Sales Status of Glipizide in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Glipizide in China, 2010-2014

5 Survey on Dosage Forms of Glipizide in China, 2010-2014

6 Reference Price of Glipizide in Chinese Hospitals in 2014

7 Major Manufacturers of Glipizide in Chinese Market, 2010-2014

8 Market Outlook of Glipizide in China, 2015-2019

Companies Mentioned

- Disha Pharmaceutical Group

- Hangzhou Conba Pharmaceutical Co., Ltd

- Pfizer

- Shandong Wanjie High-tech Co., Ltd

- Shanghai Sine Pharmaceutical Co., Ltd

- Yangtze River Pharmaceutical Group

For more information visit

http://www.researchandmarkets.com/research/l5lx3z/investigation

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets